Skip to main content
Clinical Trials/NCT06903572
NCT06903572CompletedNot Applicable

The Impact of Clinical Pharmacists Role in Transition of Care From Other Departments to Critical Care Units in Alexandria Main University Hospital.

Alexandria University1 site in 1 country126 target enrollmentStarted: April 15, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
126
Locations
1
Primary Endpoint
the number of prescriptions with accurate medication use information after transition of patients to critical care reviewed by clinical pharmacists compared to that reviewed by critical care physicians.

Study Overview

Brief Summary

Transition of care between hospital departments is an important step in patient care. Every patient may need to be transmitted either for case deterioration, improvement or interventions purposes. It includes patient transition from home to hospital, transition from one hospital to another, transition from one department to another in the same hospital, transition from hospital to home. This step has many patient safety risks due to health care teams' miscommunications, shifts handoffs and use of hard copies patients' profiles crowded with papers. So many pharmaceutical and health care organizations mentioned transition of care as one of patient and organizational related quality standards . All health care team members, including clinical pharmacists, have important roles to be played. Clinical pharmacists' services differ according to the setting at which patients are presented in.

They include medication reconciliation, resolution of medications discrepancies and medication related problems, interprofessional collaboration and communication, recommendations to patients and care givers and their engagement in the therapeutic plan and post discharge follow up .

ACCP structured task force recommendations for quality measures and associated metrics according to Avedis Donabedian's model of health care quality. Process metrics involve measuring the proportion of patients receiving transition of care services and calculating the total number of medication discrepancies and medication therapy problems and their distribution, overall and by type. Outcome measures include rates of unplanned 30 days, all cause hospital readmissions, total hospital length of stay, completion rates of first planned follow-up contact within prespecified time intervals as completion of post discharge telephone interview within 72 hours and completion rates of pharmacist-referred visits for preventive medicine or other medication-related concerns.

In this study ,the investigators will focus on clinical pharmacist services within transition in the same hospital from other department to critical care units. the investigatorswill select to measure the most important and applicable outcomes regarding this step of transition.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Health Services Research
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •All patients transmitted from any department in the hospital to critical care units.

Exclusion Criteria

  • •Patients transmitted from other hospitals.

Arms & Interventions

patients transmitted from other deprtments to to critical care department

Experimental

Intervention: the clinical pharmacists interventions about medication related information during transition of care (Other)

Outcomes

Primary Outcomes

the number of prescriptions with accurate medication use information after transition of patients to critical care reviewed by clinical pharmacists compared to that reviewed by critical care physicians.

Time Frame: 2 months

the number of prescriptions with accurate medication use information (ex: dose, indication, duration, medications should be stopped or added, medications should be monitored) , after transition of patients to critical care reviewed by clinical pharmacists compared to that reviewed by critical care physicians.

Secondary Outcomes

  • the total number of detected medication discrepancies and drug related problems and the number in each category(2 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Heba Shaker

Supervisor of clinical pharmacy units in ICU in Alexandria Main University Hospital

Alexandria University

Study Sites (1)

Loading locations...

Similar Trials